Roche's Rozlytrek (entrectinib) Receives MHLW's Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan
Shots:
- The approval is based on P-II STARTRK-2- P-I STARTRK-1- P-I ALKA-372-001 & P-I/II STARTRK-NG studies results assessing Rozlytrek in adults & pediatric patients with NTRK fusion-positive solid tumors- across 10 different tumor types- including CNS metastases solid tumors across 15 countries in 150+ clinical studies respectively
- The P-II STARTRK-2 study demonstrated that Rozlytrek shrank tumors in 50%+ patients- ORR (56.9%)- mDOR (10.4 mos.)- intracranial response (IC ORR) (50%). P-I/II STARTRK-NG resulted in shrinking tumors in children and adolescent
- Rozlytrek (RXDX-101) is a personalized oral therapy indicated for NTRK 1/2/3 LA/m-solid tumors- inhibits the kinase activity of TRK A/B/C and ROS1 protein with its expected MHLW’s approval for ROS1 fusion-positive NSCLC in Japan
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com